ProShare Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,855
| Closed | -$597K | – | 1878 |
|
|
2023
Q2 | $597K | Buy |
5,855
+376
| +7% | +$35.6K | ﹤0.01% | 876 |
|
|
2023
Q1 | $498K | Sell |
5,479
-703
| -11% | -$41.3K | ﹤0.01% | 913 |
|
|
2022
Q4 | $235K | Buy |
+6,182
| New | +$213K | ﹤0.01% | 1382 |
|
|
2022
Q2 | – | Sell |
-8,407
| Closed | -$276K | – | 2216 |
|
|
2022
Q1 | $276K | Sell |
8,407
-2,021
| -19% | -$60K | ﹤0.01% | 1685 |
|
|
2021
Q4 | $275K | Buy |
10,428
+190
| +2% | +$14.7K | ﹤0.01% | 1840 |
|
|
2021
Q3 | $1.03M | Sell |
10,238
-2,521
| -20% | -$296K | ﹤0.01% | 899 |
|
|
2021
Q2 | $1.81M | Buy |
12,759
+8,468
| +197% | +$956K | 0.01% | 759 |
|
|
2021
Q1 | $428K | Sell |
4,291
-160
| -4% | -$18.7K | ﹤0.01% | 1541 |
|
|
2020
Q4 | $550K | Sell |
4,451
-151
| -3% | -$19.8K | ﹤0.01% | 1208 |
|
|
2020
Q3 | $448K | Buy |
4,602
+102
| +2% | +$12.7K | ﹤0.01% | 989 |
|
|
2020
Q2 | $702K | Sell |
4,500
-616
| -12% | -$93.6K | ﹤0.01% | 811 |
|
|
2020
Q1 | $738K | Sell |
5,116
-3,872
| -43% | -$748K | 0.01% | 657 |
|
|
2019
Q4 | $1.84M | Buy |
8,988
+71
| +0.8% | +$13K | 0.01% | 637 |
|
|
2019
Q3 | $716K | Sell |
8,917
-213
| -2% | -$18.1K | ﹤0.01% | 863 |
|
|
2019
Q2 | $861K | Sell |
9,130
-1,104
| -11% | -$95.3K | 0.01% | 813 |
|
|
2019
Q1 | $875K | Buy |
10,234
+133
| +1% | +$11K | 0.01% | 821 |
|
|
2018
Q4 | $567K | Sell |
10,101
-1,863
| -16% | -$114K | ﹤0.01% | 904 |
|
|
2018
Q3 | $978K | Buy |
11,964
+1,388
| +13% | +$97.8K | 0.01% | 825 |
|
|
2018
Q2 | $370K | Sell |
10,576
-45
| -0.4% | -$1.37K | ﹤0.01% | 1264 |
|
|
2018
Q1 | $218K | Sell |
10,621
-1,749
| -14% | -$45K | ﹤0.01% | 1512 |
|
|
2017
Q4 | $350K | Buy |
+12,370
| New | +$345K | ﹤0.01% | 1300 |
|
Other funds holding RETA
ProShare Advisors's RETA Position: Q3 2023 in Review
ProShare Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,855 shares — an estimated $597K sold.
ProShare Advisors first reported a position in RETA in Q4 2017 and held it in 21 quarters. The position peaked at $1.84M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- ProShare Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- ProShare Advisors sold 5,855 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $597K.
- ProShare Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 21 quarters.
- ProShare Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.84M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on ProShare Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.